Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients
Conclusion: CinnaPoietin ® was proved to be non-inferior to Eprex® in the treatment of anemia in ESRD hemodialysis patients. The trial was registered in Clinicaltrials.gov (NCT03408639).Am J Nephrol 2018;48:251 –259
Source: American Journal of Nephrology - Category: Neurology Source Type: research
More News: Anemia | Chronic Kidney Disease | Clinical Trials | Dialysis | Epogen | Hemodialysis | Neurology | Procrit | Statistics | Study | Urology & Nephrology